NASDAQ
BLCM

Bellicum Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Bellicum Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$0.27
Today's High:
$0.3432
Open Price:
$0.2901
52W Low:
$0.15
52W High:
$1.55
Prev. Close:
$0.3201
Volume:
33308

Company Statistics

Market Cap.:
$2.33 million
Book Value:
-1.108
Revenue TTM:
$1.51 million
Operating Margin TTM:
-1968.63%
Gross Profit TTM:
$-17378000
Profit Margin:
0%
Return on Assets TTM:
-61.14%
Return on Equity TTM:
-106.13%

Company Profile

Bellicum Pharmaceuticals Inc had its IPO on 2014-12-18 under the ticker symbol BLCM.

The company operates in the Healthcare sector and Biotechnology industry. Bellicum Pharmaceuticals Inc has a staff strength of 13 employees.

Stock update

Shares of Bellicum Pharmaceuticals Inc opened at $0.29 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.27 - $0.34, and closed at $0.34.

This is a +6.22% increase from the previous day's closing price.

A total volume of 33,308 shares were traded at the close of the day’s session.

In the last one week, shares of Bellicum Pharmaceuticals Inc have increased by +6.25%.

Bellicum Pharmaceuticals Inc's Key Ratios

Bellicum Pharmaceuticals Inc has a market cap of $2.33 million, indicating a price to book ratio of 1.005 and a price to sales ratio of 5.4552.

In the last 12-months Bellicum Pharmaceuticals Inc’s revenue was $1.51 million with a gross profit of $-17378000 and an EBITDA of $-29678000. The EBITDA ratio measures Bellicum Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Bellicum Pharmaceuticals Inc’s operating margin was -1968.63% while its return on assets stood at -61.14% with a return of equity of -106.13%.

In Q1, Bellicum Pharmaceuticals Inc’s quarterly earnings growth was a negative -93.3% while revenue growth was a positive 0%.

Bellicum Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bellicum Pharmaceuticals Inc’s profitability.

Bellicum Pharmaceuticals Inc stock is trading at a EV to sales ratio of 1.3294 and a EV to EBITDA ratio of 2.3808. Its price to sales ratio in the trailing 12-months stood at 5.4552.

Bellicum Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$17.26 million
Total Liabilities
$4.72 million
Operating Cash Flow
$0
Capital Expenditure
$5000
Dividend Payout Ratio
0%

Bellicum Pharmaceuticals Inc ended 2024 with $17.26 million in total assets and $0 in total liabilities. Its intangible assets were valued at $17.26 million while shareholder equity stood at $-10020000.00.

Bellicum Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $4.72 million in other current liabilities, 91000.00 in common stock, $-583491000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $15.40 million and cash and short-term investments were $15.40 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Bellicum Pharmaceuticals Inc’s total current assets stands at $17.24 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $8000.00 compared to accounts payable of $1.23 million and inventory worth $0.

In 2024, Bellicum Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $5000.

Comparatively, Bellicum Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.34
52-Week High
$1.55
52-Week Low
$0.15
Analyst Target Price
$5

Bellicum Pharmaceuticals Inc stock is currently trading at $0.34 per share. It touched a 52-week high of $1.55 and a 52-week low of $1.55. Analysts tracking the stock have a 12-month average target price of $5.

Its 50-day moving average was $0.41 and 200-day moving average was $0.65 The short ratio stood at 0.17 indicating a short percent outstanding of 0%.

Around 419.7% of the company’s stock are held by insiders while 2930.5% are held by institutions.

Frequently Asked Questions About Bellicum Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Bellicum Pharmaceuticals Inc is BLCM

The IPO of Bellicum Pharmaceuticals Inc took place on 2014-12-18

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
EICHER MOTORS LTD. (EICHERMOT)
$3341.6
-62.85
-1.85%
$15.73
-0.01
-0.06%
$6.43
0.21
+3.38%
$153
1.62
+1.07%
$6.05
0.02
+0.33%
$2.68
-0.03
-1.11%
$77.67
0.09
+0.12%
$0.57
0.13
+30.14%
$43.14
0.43
+1.01%
$112.9
-1
-0.88%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company’s clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

Address

3730 Kirby Drive, Houston, TX, United States, 77098